ReviewCancers2022
Prognostic and Predictive Role of Tumor-Infiltrating Lymphocytes (TILs) in Ovarian Cancer.
Review in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 42 citations in OpenAlex.
- Tumour-Stroma Ratio and Platinum Resistance in Epithelial Ovarian Cancer: An Exploratory Analysis.Cancers · 2026Article
- Preoperative Inflammatory Markers as Predictors of Ovarian Tumor Malignancy: A Retrospective Diagnostic Study.Medicina (Kaunas, Lithuania) · 2026Observational
- AI-Based Analysis of Tumor-Infiltrating Lymphocytes and Homologous Recombination in Ovarian Cancer: JGOG3025-A1 Study.Cancer science · 2026Article
- Single-cell RNA sequencing in ovarian cancer: decoding the tumor microenvironment for personalized therapy.Journal of ovarian research · 2026Review
- Immunocyte senescence: A new perspective on the remodeling of the ovarian cancer microenvironment and therapeutic intervention.Journal of pharmaceutical analysis · 2026Review
- Treatment Advances in Gynecologic Cancers: Insights From Recent Clinical Trials.Cancer innovation · 2026Review
- Distinct immune microenvironments in ovarian cancer subtypes indicate potential for immunotherapies.Journal of translational medicine · 2026Article
- AI-based quantification of tumor-infiltrating lymphocytes with integrative transcriptomics in ovarian clear cell carcinoma: JGOG3025-TR1/A1 study.Cancer immunology, immunotherapy : CII · 2026Article
- Tumor-embedded Immunity and TRM Cell Functions in Cancer.Mini reviews in medicinal chemistry · 2026Review
- Neoadjuvant chemotherapy-induced immune remodeling in ovarian cancer: implications for TIL dynamics and combination immunotherapy.Frontiers in immunology · 2026Review
- Review
- The Search for Predictive Biomarkers in Response to Immune Checkpoint Inhibitors and Associated Adverse Events.Journal of personalized medicine · 2025Review
- Prognostic significance of tumour-infiltrating T lymphocytes in ovarian cancer: a protocol for systematic review and meta-analysis.BMJ open · 2025Article
- Immunotherapy and Advanced Vulvar Cancer: A Systematic Review and Meta-Analysis of Survival and Safety Outcomes.Cancers · 2025Review
- Article
- From Defense to Disease: How the Immune System Fuels Epithelial-Mesenchymal Transition in Ovarian Cancer.International journal of molecular sciences · 2025Review
- Review
- Tumor-infiltrating lymphocytes are the key determinants of pathological features associated with pathogenicFrontiers in medicine · 2025Article
- Article
- Bevacizumab in ovarian cancer therapy: current advances, clinical challenges, and emerging strategies.Frontiers in bioengineering and biotechnology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the last decade, tumor-infiltrating lymphocytes (TILs) have been recognized as clinically relevant prognostic markers for improved survival, providing the immunological basis for the development of new therapeutic strategies and showing a significant prognostic and predictive role in several malignancies, including ovarian cancer (OC). In fact, many OCs show TILs whose typology and degree of infiltration have been shown to be strongly correlated with prognosis and survival. The OC histological subtype with the higher presence of TILs is the high-grade serous carcinoma (HGSC) followed by the endometrioid subtype, whereas mucinous and clear cell OCs seem to contain a lower percentage of TILs. The abundant presence of TILs in OC suggests an immunogenic potential for this tumor. Despite the high immunogenic potential, OC has been described as a highly immunosuppressive tumor with a high expression of PD1 by TILs. Although further studies are needed to better define their role in prognostic stratification and the therapeutic implication, intraepithelial TILs represent a relevant prognostic factor to take into account in OC. In this review, we will discuss the promising role of TILs as markers which are able to reflect the anticancer immune response, describing their potential capability to predict prognosis and therapy response in OC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.